Research programme: second generation T cell receptor therapeutics - Kite Pharma/bluebird bio

Drug Profile

Research programme: second generation T cell receptor therapeutics - Kite Pharma/bluebird bio

Alternative Names: Second generation HPV-16 E6 TCR - Kite/bluebird bio; Second generation TCR therapeutics - Kite Pharma/bluebird bio

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator bluebird bio; Kite Pharma
  • Developer Kite Pharma
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E6 T cell receptor expression modulators; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Apr 2017 Preclinical development of second generation HPV-16 E6 TCR for HPV-associated Cancers is ongoing in USA (Parenteral)
  • 22 Jun 2015 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top